China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy

Novo Nordisk announced that China's drug regulator has accepted its application to sell the oral version of its GLP-1 weight-loss drug, Wegovy. This move signifies Novo Nordisk's efforts to expand its presence in the world's second-largest pharmaceutical market.